A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. - Wikidata - awgldk - TriplyDB

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.

http://www.wikidata.org/entity/Q33394505

about

Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis Systemic therapy for metastatic pancreatic adenocarcinoma.Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis

P2860

Q28066268-F8581578-E752-41FF-80A6-90131E927219 Q33754779-A2BE713A-0E42-48F4-8A6F-57BE8B60CF86 Q35076238-721E3287-325A-4DA9-B5DD-4DC12CD1DC7E Q36018926-9B352FFC-88A0-40CD-88E6-18152B74860C Q36228534-DABA94E0-F132-42AF-95BA-8AC11B6B5170 Q36384541-C02EDBF8-8119-490D-8F45-6B11600E482B Q36570306-7CEEAA6F-3333-4DBE-AAC4-08D569C148FB Q37268613-A85C4088-023B-4133-9978-74F83F4B24CF Q37354440-813064BC-3CE8-4A2A-BFAF-945C42EE13E2 Q57817700-A1FE68EC-33B9-4585-BE22-C2245535A23C

P2860

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.

http://www.wikidata.org/entity/Q33394505

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A phase II trial of erlotinib ...... s with translational research.

@ast

A phase II trial of erlotinib ...... s with translational research.

@en

type

label

A phase II trial of erlotinib ...... s with translational research.

@ast

A phase II trial of erlotinib ...... s with translational research.

@en

prefLabel

A phase II trial of erlotinib ...... s with translational research.

@ast

A phase II trial of erlotinib ...... s with translational research.

@en

P1433

Q33394505-E0009C61-6503-4A7A-8FC6-99C9D2681ED3

P1476

Q33394505-925AAB88-042D-4AD7-A2B6-51762D910E34

P2093

Q33394505-13EB1C2C-7B74-4346-AFA7-15646CCA11D9

Q33394505-4EB7C35E-EABF-4AF7-BB1A-C8DF0A6380C6

Q33394505-51C18A19-50E0-4707-A0AF-0316D3E111BD

Q33394505-5A605437-D9AD-40B5-9AB4-788AE86414FC

Q33394505-5A6A991F-A786-4328-B610-FB0D14EAD9E9

Q33394505-5F833C96-1609-4BA7-9765-498A9E8887F0

Q33394505-8F3CD761-812B-4A33-A3D9-182C4C8422C5

Q33394505-9F274A44-896D-49FE-925D-39A3561ECE2B

Q33394505-A63F7B40-4024-41BC-B2DC-BD672F762375

Q33394505-B5BA058F-A8A3-4D8C-A38B-3677C7C24CD2

P2860

Q33394505-0C697946-2528-4246-BCFE-C74F9D68FFF1

Q33394505-0F9758E3-29A3-4B45-901E-CE263370D322

Q33394505-13652994-6100-4923-99A0-FF41A874A1EB

Q33394505-3DFD76CB-ECCC-4BAC-8C49-BC605C2B7C4C

Q33394505-4850BBB2-E007-45D3-9C38-768871D7361B

Q33394505-4B9D31A1-1115-4606-ACEF-BDE2E39D1D5B

Q33394505-4DC44984-943E-4558-B6EC-1326468F6D88

Q33394505-65EBDE38-37CE-4C3F-BB25-C96B1071165E

Q33394505-6700B38D-9F92-4918-8233-4E594FFD05D7

Q33394505-69988FAC-D6B8-4D98-A6E4-5CBD0DB0D812

P2888

Q33394505-018F4A6B-E99B-476C-ABF7-5DCF7BAA34E8

P304

Q33394505-4AE3F8BE-4261-4046-B348-4E5618176B35

P31

Q33394505-A7C1BFD0-FDBE-467F-AB75-25FC2562172E

P356

Q33394505-B4BE3667-B6F7-487C-AE79-DCCAD7F77B43

P433

Q33394505-1790ADBA-05C2-4C1B-9690-7ED609B36F76

P478

Q33394505-4655307D-FE3A-45F7-A200-F2E3A51270B6

P577

Q33394505-DC741645-CFA3-4035-9499-71343C3EE8EE

P5875

Q33394505-334A9694-F87E-4BDA-A279-18837B8C5768

P6179

Q33394505-E6ED057C-5506-4AB1-8C20-A44C9E69BA56

P698

Q33394505-7D18505B-C938-40D5-BB35-614C3B713B99

P921

Q33394505-98837D8C-53D4-4952-A664-BDC3B947A899

P356

S10637-011-9651-3

P1433

Investigational New Drugs

P1476

A phase II trial of erlotinib ...... s with translational research.

@en

P2093

Bong-Seog Kim

http://www.w3.org/2001/XMLSchema#string

Chang-Hak Sohn

http://www.w3.org/2001/XMLSchema#string

Dae Young Zang

http://www.w3.org/2001/XMLSchema#string

Do-Youn Oh

http://www.w3.org/2001/XMLSchema#string

Hong-Suk Song

http://www.w3.org/2001/XMLSchema#string

Hun-Mo Ryoo

http://www.w3.org/2001/XMLSchema#string

Hye-Jin Kang

http://www.w3.org/2001/XMLSchema#string

Jin-Soo Kim

http://www.w3.org/2001/XMLSchema#string

Keun Wook Lee

http://www.w3.org/2001/XMLSchema#string

Kyung-Hee Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

Cancer pharmacogenetics.

P2888

s10637-011-9651-3

P304

1164-1174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-011-9651-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50396236

http://www.w3.org/2001/XMLSchema#string

P6179

1049174669

http://www.w3.org/2001/XMLSchema#string

P698

21404106

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial